Thiopurine immunomodulators still represent a potentially inexpensive and effective therapy for inflammatory bowel disease (IBD) maintenance even in the advent of biologics, according to a leading gastroenterologist.
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Unusual involvement of the eyes with atypical presentations may occur in patients with inflammatory bowel diseases (IBD) on antitumour necrosis factor (anti-TNF) therapy, according to a recent study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.
In patients with ulcerative colitis (UC), changes in histologic and endoscopic scores appear to be weakly to moderately predictive of each other, according to an analysis of the HICKORY study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).
Most patients with moderately to severely active ulcerative colitis and Crohn’s disease on vedolizumab persist with their treatment for up to 5 years, according to a posthoc analysis of the phase III GEMINI long-term safety (LTS) study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting.
The use of oral liposomal iron in the treatment of mild anaemia in inflammatory bowel disease (IBD) patients appears to be effective, producing improvements in haemoglobin levels and quality of life with parallel reductions in fatigue, according to a study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting.
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.